Loading clinical trials...
Loading clinical trials...
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
Conditions
Interventions
Sofosbuvir/Velpatasvir
Sofosbuvir/Velpatasvir/Voxilaprevir
Locations
6
United States
University of California, San Francisco
San Francisco, California, United States
University of Colorado Denver
Aurora, Colorado, United States
Piedmont Research Institute
Atlanta, Georgia, United States
Columbia University
New York, New York, United States
Baylor University Medical Center - Dallas
Dallas, Texas, United States
Houston Methodist Hospital
Houston, Texas, United States
Start Date
July 15, 2018
Primary Completion Date
December 21, 2019
Completion Date
August 13, 2020
Last Updated
March 3, 2021
NCT06953479
NCT04162938
NCT03135886
NCT05968573
NCT01644903
NCT05368974
Lead Sponsor
University of California, San Francisco
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions